阿斯利康长效C5补体抑制剂在国内获批;信立泰营收、扣非利润双降

Ofweek光电信息网
23 Apr

阿斯利康又一重磅产品在国内获批。4月22日,阿斯利康宣布,长效C5补体抑制剂伟立瑞在中国正式获批,与常规治疗药物联合用于治疗抗乙酰胆碱受体(AChR)抗体阳性的成人全身型重症肌无力(gMG)患者。疫苗一哥业绩暴雷。4月21日,智飞生物发布2024年财报和2025年一季报。2024年,公司收入260亿元,同比下滑50.74%;净利润20.18亿元,同比下滑74.99%。2025年一季度,公司收入...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10